Literature DB >> 31831267

Degradation of Polycomb Repressive Complex 2 with an EED-Targeted Bivalent Chemical Degrader.

Frances Potjewyd1, Anne-Marie W Turner2, Joshua Beri3, Justin M Rectenwald4, Jacqueline L Norris-Drouin1, Stephanie H Cholensky1, David M Margolis5, Kenneth H Pearce1, Laura E Herring3, Lindsey I James6.   

Abstract

Protein degradation via the use of bivalent chemical degraders provides an alternative strategy to block protein function and assess the biological roles of putative drug targets. This approach capitalizes on the advantages of small-molecule inhibitors while moving beyond the restrictions of traditional pharmacology. Here, we report a chemical degrader (UNC6852) that targets polycomb repressive complex 2 (PRC2). UNC6852 contains an EED226-derived ligand and a ligand for VHL which bind to the WD40 aromatic cage of EED and CRL2VHL, respectively, to induce proteasomal degradation of PRC2 components, EED, EZH2, and SUZ12. Degradation of PRC2 with UNC6852 blocks the histone methyltransferase activity of EZH2, decreasing H3K27me3 levels in HeLa cells and diffuse large B cell lymphoma (DLBCL) cells containing EZH2 gain-of-function mutations. UNC6852 degrades both wild-type and mutant EZH2, and additionally displays anti-proliferative effects in this cancer model system.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Proteolysis-Targeting Chimera (PROTAC); bivalent chemical degrader; diffuse large B cell lymphoma (DLBCL); embryonic ectoderm development (EED); enhancer of zeste homolog 2 (EZH2); histone methyltransferase (HMT); polycomb repressive complex 2 (PRC2); suppressor of zeste homolog 12 (SUZ12); von Hippel-Lindau (VHL)

Mesh:

Substances:

Year:  2019        PMID: 31831267      PMCID: PMC7004250          DOI: 10.1016/j.chembiol.2019.11.006

Source DB:  PubMed          Journal:  Cell Chem Biol        ISSN: 2451-9448            Impact factor:   8.116


  50 in total

1.  EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.

Authors:  Michael T McCabe; Heidi M Ott; Gopinath Ganji; Susan Korenchuk; Christine Thompson; Glenn S Van Aller; Yan Liu; Alan P Graves; Anthony Della Pietra; Elsie Diaz; Louis V LaFrance; Mark Mellinger; Celine Duquenne; Xinrong Tian; Ryan G Kruger; Charles F McHugh; Martin Brandt; William H Miller; Dashyant Dhanak; Sharad K Verma; Peter J Tummino; Caretha L Creasy
Journal:  Nature       Date:  2012-10-10       Impact factor: 49.962

2.  Total synthesis, structural revision and biological evaluation of γ-elemene-type sesquiterpenes.

Authors:  Changchun Yuan; Shangyong Zhong; Xingyi Li; Yanhong Wang; Miao-Miao Xun; Yunli Bai; Kongkai Zhu
Journal:  Org Biomol Chem       Date:  2018-10-31       Impact factor: 3.876

3.  A General TR-FRET Assay Platform for High-Throughput Screening and Characterizing Inhibitors of Methyl-Lysine Reader Proteins.

Authors:  Justin M Rectenwald; P Brian Hardy; Jacqueline L Norris-Drouin; Stephanie H Cholensky; Lindsey I James; Stephen V Frye; Kenneth H Pearce
Journal:  SLAS Discov       Date:  2019-04-24       Impact factor: 3.341

4.  Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors.

Authors:  V Gibaja; F Shen; J Harari; J Korn; D Ruddy; V Saenz-Vash; H Zhai; T Rejtar; C G Paris; Z Yu; M Lira; D King; W Qi; N Keen; A Q Hassan; H M Chan
Journal:  Oncogene       Date:  2015-04-20       Impact factor: 9.867

Review 5.  Writing, erasing and reading histone lysine methylations.

Authors:  Kwangbeom Hyun; Jongcheol Jeon; Kihyun Park; Jaehoon Kim
Journal:  Exp Mol Med       Date:  2017-04-28       Impact factor: 8.718

6.  Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACs.

Authors:  Miriam Girardini; Chiara Maniaci; Scott J Hughes; Andrea Testa; Alessio Ciulli
Journal:  Bioorg Med Chem       Date:  2019-02-22       Impact factor: 3.641

7.  Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase.

Authors:  Blake E Smith; Stephen L Wang; Saul Jaime-Figueroa; Alicia Harbin; Jing Wang; Brian D Hamman; Craig M Crews
Journal:  Nat Commun       Date:  2019-01-10       Impact factor: 14.919

8.  Cryo-EM structures of PRC2 simultaneously engaged with two functionally distinct nucleosomes.

Authors:  Simon Poepsel; Vignesh Kasinath; Eva Nogales
Journal:  Nat Struct Mol Biol       Date:  2018-01-29       Impact factor: 15.369

Review 9.  Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs.

Authors:  Sainan An; Liwu Fu
Journal:  EBioMedicine       Date:  2018-09-14       Impact factor: 8.143

Review 10.  The PROTAC technology in drug development.

Authors:  Yutian Zou; Danhui Ma; Yinyin Wang
Journal:  Cell Biochem Funct       Date:  2019-01-02       Impact factor: 3.685

View more
  37 in total

Review 1.  Preclinical and Clinical Advances of Targeted Protein Degradation as a Novel Cancer Therapeutic Strategy: An Oncologist Perspective.

Authors:  Xinrui Yang; He Yin; Richard D Kim; Jason B Fleming; Hao Xie
Journal:  Target Oncol       Date:  2020-12-28       Impact factor: 4.493

Review 2.  Proteolysis-targeting chimeras in drug development: A safety perspective.

Authors:  Kevin Moreau; Muireann Coen; Andrew X Zhang; Fiona Pachl; M Paola Castaldi; Goran Dahl; Helen Boyd; Clay Scott; Pete Newham
Journal:  Br J Pharmacol       Date:  2020-02-25       Impact factor: 8.739

Review 3.  Lysine methyltransferase inhibitors: where we are now.

Authors:  Alessandra Feoli; Monica Viviano; Alessandra Cipriano; Ciro Milite; Sabrina Castellano; Gianluca Sbardella
Journal:  RSC Chem Biol       Date:  2021-12-13

Review 4.  Domain cross-talk in regulation of histone modifications: Molecular mechanisms and targeting opportunities.

Authors:  James E Longbotham; Meng Yao Zhang; Danica Galonić Fujimori
Journal:  Curr Opin Chem Biol       Date:  2020-08-03       Impact factor: 8.822

Review 5.  Critical Assessment of Targeted Protein Degradation as a Research Tool and Pharmacological Modality.

Authors:  Milka Kostic; Lyn H Jones
Journal:  Trends Pharmacol Sci       Date:  2020-03-26       Impact factor: 14.819

6.  Getting a handle on chemical probes of chomatin readers.

Authors:  Jarod M Waybright; Lindsey I James
Journal:  Future Med Chem       Date:  2020-01-10       Impact factor: 3.808

Review 7.  Ubiquitin-dependent regulation of transcription in development and disease.

Authors:  Kevin G Mark; Michael Rape
Journal:  EMBO Rep       Date:  2021-03-28       Impact factor: 8.807

Review 8.  The control of polycomb repressive complexes by long noncoding RNAs.

Authors:  Jackson B Trotman; Keean C A Braceros; Rachel E Cherney; McKenzie M Murvin; J Mauro Calabrese
Journal:  Wiley Interdiscip Rev RNA       Date:  2021-04-16       Impact factor: 9.957

Review 9.  Noncanonical Functions of the Polycomb Group Protein EZH2 in Breast Cancer.

Authors:  Talha Anwar; Maria E Gonzalez; Celina G Kleer
Journal:  Am J Pathol       Date:  2021-02-06       Impact factor: 4.307

Review 10.  Advancing targeted protein degradation for cancer therapy.

Authors:  Brandon Dale; Meng Cheng; Kwang-Su Park; H Ümit Kaniskan; Yue Xiong; Jian Jin
Journal:  Nat Rev Cancer       Date:  2021-06-15       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.